Biomedical subjects

M A Rettenmaier

Publications and source records attributed to M A Rettenmaier.

41 records · Page 3Linked to original sources

PubMed1983

In vivo antineoplastic activity of various biological response modifiers for tumors of the ovary and breast.

Fourteen pharmacologic agents reported to have biological activities which are directly or indirectly antineoplastic, were assayed for their ability to inhibit the growth of a mouse neoplasia (M5076) and a rat mammary adenocarcinoma (13762) implanted beneath the renal capsule of the host. Ascorbic acid, cimetidine hydrochloride. Corynebacterium parvum, dimethylsulfoxide, naloxone hydrochloride, indomethacin, muramyl-dipeptide, Protein A from Staphylococcus aureus, theophylline, tilorone (analog R11, 877DA), tuftsin diacetate and sodium ibuprofen were completely inactive as antineoplastic agents for these 2 tumors. In fact, theophylline and dimethylsulfoxide seemed to enhance the formation of 13762 metastases. Blue tongue virus and polyinocinic-polycytidylic acid were marginally effective antineoplastic agents for 13762. Polyinocinic-polycytidylic acid was an excellent antineoplastic agent for M5076; this agent not only prevented the growth of M5076, it was oncolytic.

Adjuvants, Immunologic↗

PubMed1983

A comparative study of two types of prostaglandins for abortion during the second trimester.

A comparative study of two techniques of prostaglandin midtrimester abortion was performed. Patients were randomly assigned to either intra-amniotic prostaglandin F2 alpha or intravaginal prostaglandin E2 methods. Mean induction to abortion intervals were 9.99 +/- 6.18 and 9.19 +/- 2.59 hours, respectively. The incidence of side-effects for the two methods was similar. Both prostaglandin F2 alpha and E2 are considered to represent equivalent midtrimester abortifacients.

Abortifacient Agents, Nonsteroidal↗

PubMed1983

Accurate predictions of tumor growth in vivo: the subrenal capsule implant site.

An assay system with exquisite predictive qualities is described for four animal tumors: two rat mammary adenocarcinomas, R3230 Ac and 13762; a mouse papillary mammary carcinoma, MXT; and the mouse reticulum cell sarcoma M5076. The tumors were implanted beneath the renal capsule of syngeneic hosts (BDF1 mice or Fischer 344 rats). This site is readily accessible, well-protected, and provides a rich vascular bed, thus controlling many of the variables involved in neoplastic growth. The growth of each implant was recorded as a function of time and/or the initial tumor size. The absolute growth of each of the tumors could be predicted accurately from a simple linear regression analysis of time (i.e., number of days post-implant). Even more accurate predictions of tumor growth were obtained when both variables (days post-implant and initial implant size) were evaluated by multiple regression analysis. The subrenal capsule tumor implant site provides a superior model system to investigate the effects of biological response modifiers and other immunological manipulations on tumor growth in intact normal immunocompetent animals.

Animals↗

PubMedDate not supplied

Spontaneous bacterial peritonitis following treatment for cervical carcinoma.

Spontaneous bacterial peritonitis (SBP) is an acute bacterial infection usually associated with ascites and cirrhosis or is a complication of peritoneal dialysis. There are very few case reports of cancer patients who developed this disease. Furthermore, there have been no published case reports of successfully treated gynecological cancer patients who later developed SBP. We present a case involving a 41-year-old woman who was treated for cervical carcinoma in 1992. She underwent radical surgery and adjuvant chemoradiation therapy. Two years later, the patient presented with streptococcal group B cellulitis associated with left leg lymphedema. She recovered following antibiotic treatment but had recurrent episodes of streptococcal cellulitis in her leg over the past 10 years. In 2003, the patient was admitted to the hospital because of sepsis, acute renal failure, and SBP. She was treated and recovered following treatment. SBP is usually associated with cirrhosis. Although SBP is rarely seen in successfully treated gynecological cancer patients, oncologists should be aware of this clinical entity. Timely treatment is essential to maximize chances of survival.

Adult↗

PubMedDate not supplied

Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma.

The management of stage IB2 cervical carcinoma remains controversial. This retrospective review evaluates 47 IB2 cervical carcinoma patients treated with surgery alone (S), surgery plus postoperative radiotherapy (SR), or surgery plus postoperative chemoradiation (SRC). Median progression-free interval (PFI) was 70.3 months for the SR group (n= 21), 73.3 months for the SRC group (n= 15), and 33.5 months for the S group (n= 11). The survival rate was 76% for the SR group, 87% for the SRC group, and 55% for the S group. Overall 5-year survival rate for the three groups was 75%. Median follow-up for the patient population was 61.3 months. The number of the patient and the nonrandomized nature of this study preclude any definitive conclusions, but interestingly, the SRC and SR groups exhibited a substantially better PFI and overall survival compared to the S group. Selection bias does not appear to be a factor since patients in SR or SRC group were at greater risk for recurrence (eg, higher incidence of deep stromal invasion, parametrial involvement) than patients in the S group; yet, they still experienced superior PFI and overall survival. Further studies comparing postoperative irradiation and chemoradiation with these patients in a randomized phase 3 trial may be warranted.

Adenocarcinoma↗